Lymphatic Diseases Clinical Trial
Official title:
Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Verified date | March 2022 |
Source | Fondazione Italiana Linfomi ONLUS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of Brentuximab Vedotin (BV) as a single agent in relapsed/refractory CD30+ PTCL patients.
Status | Completed |
Enrollment | 25 |
Est. completion date | March 2022 |
Est. primary completion date | September 24, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Signed written informed consent. - Males and females =18 and =75 years at the time of enrolment. - Histologically confirmed diagnosis of PTCL (PTCL-not otherwise specified [PTCL-NOS], angioimmunoblastic T cell lymphoma [AILT] and transformed mycosis fungoides) according to World Health Organization (2008) classification. - Histologically confirmed CD30+ PTCL. - Availability of histological material for central review and pathobiological studies. - Failed at least one prior systemic antilymphoma therapy. - Eastern Cooperative Oncology Group (ECOG) performance status score of = 1 at study entry. - At least one site of disease measurable in two dimensions by computed tomography. Both nodal and extranodal disease will be considered (lymphnodes must have long axis of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 cm and short axis >1.0 cm). - Hematology values within the following limits: - Absolute neutrophil count (ANC) = 1500/mm3 independent of growth factor support. - Platelets =75,000/mm3 or =50,000/mm3 if bone marrow involvement is independent of transfusion support. - Hemoglobin level =8 g/dL. - Biochemical values within the following limits: - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN). - Total bilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin). - Serum creatinine = 2 x ULN. - Serum albumin = 3 g/dL. - Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication. - WOCBP must agree to use effective contraception, defined as oral contraceptives, double barrier method or practice true abstinence from sexual intercourse during the study and for 6 months after the last dose of study drug. - Male subjects and their female partners of childbearing potential must be willing to use an appropriate method of contraception or practice true abstinence from sexual intercourse during the study and for 6 months after the last dose of study drug. Exclusion Criteria: - Diagnosis of CTCL, ALCL, mycosis fungoides or Sezary Syndrome. - CD30 expression < 10 %. - Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives of last dose of that prior treatment. - Patients underwent major surgery without complete recovery - Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin. - Any serious active disease or co-morbid medical condition (according to investigator's decision). - Prior history of malignancies other than lymphoma (except for a history of a complete resection for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for = 3 years. - Patients with peripheral neuropathy of grade 3-4 (also grade 2 with persistent pain, unresponsive to treatment). - Signs or symptoms of progressive multifocal leukoencephalopathy (PML). - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. - Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study. - CNS disease (meningeal and/or brain involvement by lymphoma) or testicular involvement. - History of clinically relevant liver or renal insufficiency; significant cardiac, vascular pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances. - Known history of any of the following cardiovascular conditions: - Myocardial infarction within 2 years from enrollment - New York Heart Association (NYHA) Class III or IV heart failure - Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities - Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50% - Active opportunistic infection. - Known history of Human Immunodeficiency Virus (HIV) or Hepatitis C or active infection with Hepatitis B. - Prior allogeneic stem cell transplant. |
Country | Name | City | State |
---|---|---|---|
Italy | Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi | Bologna | |
Italy | Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori | Milano | |
Italy | SC Ematologia - Città della Salute e della Scienza | Torino | |
Italy | A.O. Universitaria S. Maria Della Misericordia Di Udine | Udine |
Lead Sponsor | Collaborator |
---|---|
Fondazione Italiana Linfomi ONLUS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Event-Free survival (EFS) | Event-free survival (EFS) is defined as the time from start of study treatment to any treatment failure including disease progression, or discontinuation of treatment for any reason | 1 year | |
Other | B symptom resolution rate | B symptom resolution rate is defined as the proportion of patients with lymphoma-related B symptoms at baseline who achieve resolution of all B symptoms at any time during the treatment period. | 1 year | |
Other | CD30 expression | Correlation between CD30 expression and response | 1 year | |
Primary | overall objective response rate (ORR) | Overall objective response rate (ORR) is defined as the proportion of patients with complete remission (CR) or partial remission (PR) according to the Revised Response Criteria for Malignant Lymphoma | 1 year | |
Secondary | Duration of response | Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to lymphoma | 1 year | |
Secondary | Complete remission rate (CR) | The proportion of patients with complete remission (CR) according to the Revised Response Criteria for Malignant Lymphoma | 1 year | |
Secondary | Progression-free survival (PSF) | Progression-free survival (PFS) is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause | 1 year | |
Secondary | Overall survival (OS) | Overall survival (OS) is defined as the time from start of study treatment to date of death due to any cause. | 1 year | |
Secondary | Adverse Events | Type, incidence, severity, seriousness, and relatedness of adverse events, and laboratory abnormalities | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01451502 -
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
|
N/A | |
Active, not recruiting |
NCT03264131 -
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
|
Phase 2 | |
Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 | |
Completed |
NCT02335242 -
Sildenafil for the Treatment of Lymphatic Malformations
|
Phase 2 | |
Completed |
NCT03135535 -
Micro-mobile Foot Compression and Diabetic Foot
|
Phase 2 | |
Active, not recruiting |
NCT05441943 -
Lymphaticovenous Anastomosis as Treatment for Lymphedema
|
N/A | |
Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
Withdrawn |
NCT05431179 -
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05731141 -
A Prospective Natural History Study of Lymphatic Anomalies
|
||
Recruiting |
NCT03696784 -
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
|
Phase 1 | |
Completed |
NCT03709407 -
"Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study"
|
N/A | |
Active, not recruiting |
NCT02663297 -
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
|
Phase 1 | |
Completed |
NCT05683444 -
Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial
|
Early Phase 1 | |
Completed |
NCT02960841 -
Effectiveness of Intracavitary Manual Lymphatic Drainage
|
Phase 4 | |
Recruiting |
NCT05263583 -
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02499627 -
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
|
Phase 2 | |
Recruiting |
NCT03373019 -
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 2 | |
Recruiting |
NCT03602157 -
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
|
Phase 1 | |
Recruiting |
NCT02690545 -
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
|
Phase 1/Phase 2 | |
Completed |
NCT02744027 -
Imaging of Lymphatic Anomalies
|
N/A |